Skip to Content

Juramate (Canada)

This page contains information on Juramate for veterinary use.
The information provided typically includes the following:
  • Juramate Indications
  • Warnings and cautions for Juramate
  • Direction and dosage information for Juramate

Juramate

This treatment applies to the following species:
Manufacturer: Bimeda-MTC

DIN 02337967

For Veterinary Use Only

Cloprostenol Injection BP 250 µg/mL (as cloprostenol sodium BP)

Sterile solution for intramuscular injection only in cattle

Synthetic prostaglandin analogue for cattle

Description

Juramate, a colourless, aqueous solution, contains 250 µg/mL cloprostenol (equivalent to 263 µg/mL cloprostenol sodium) in an isotonic citrate buffer containing 1 mg/mL (0.1% w/v) chlorocresol as preservative.

Clinical Pharmacology

Cloprostenol is a synthetic prostaglandin analogue structurally related to Prostaglandin F (PGF). It causes functional and morphological regression of the corpus luteum in cattle. This effect on the life span of the corpus luteum usually results in estrus 2 - 5 five days after treatment, followed by ovulation with normal fertility. Juramate alone will not increase fertility.

Juramate Indications

By its ability to shorten the life span of the corpus luteum, Juramate can be used to treat certain clinical conditions which delay breeding, to manipulate the estrous cycle to better fit certain management practices, and to induce abortion.

1. therapeutic Indications

Sub-estrus (silent Heat Or Non-detected Estrus)

Cows which fail to exhibit normal estrous behaviour, although ovarian cyclicity continues can be treated with Juramate while in the luteal phase of the estrous cycle. They may then either be closely observed for estrus over a scheduled time period and bred on detection of estrus or bred at 72 and 96 hours after injection without estrus detection.

Pyometra or chronic endometritis: Damage to the reproductive tract at calving or postpartum retention of the placenta frequently leads to infection and inflammation of the uterus which is usually referred to as endometritis. Under certain circumstances, this may progress into chronic endometritis with the uterus becoming distended with purulent matter. This condition, frequently referred to as pyometra, is characterized by lack of cyclical estrous behaviour and the presence of a persistent corpus luteum. This condition can be successfully treated by causing regression of the corpus luteum by treatment with Juramate. Where necessary, treatment may be repeated after 10 - 14 days.

Pregnancies from mis-mating: Unwanted pregnancies can be safely and efficiently terminated from one week after mating until about 4 1/2 months of gestation. The induced abortion is uncomplicated, the fetus and placenta are usually expelled about 4 or 5 days after the injection, and the reproductive tract returns to normal soon after the abortion. Trial results have demonstrated that an abortion rate of approximately 95% can be expected up to 4 1/2 months of gestation. The ability of cloprostenol to induce abortion decreases beyond 4 1/2 months while the risk of dystocia and its consequences increases.

Mummified fetus: Death of the conceptus during gestation may be followed by its degeneration and dehydration. Induction of luteolysis with cloprostenol usually results in the expulsion of the mummified fetus from the uterus. (Manual assistance may be necessary to remove the fetus from the vagina. Normal cyclical activity should then follow).

2. Controlled breeding: The luteolytic action of Juramate can be used to schedule estrus and ovulation for an individual animal or a group of animals. This allows control of the time at which cycling cows or heifers can be bred.

3. Abortion in feedlot heifers: Unwanted pregnancies can be safely and efficiently terminated from one week after mating until about 4 1/2 months of gestation. The induced abortion is uncomplicated, the fetus and placenta are usually expelled about 4 or 5 days after the injection, and the reproductive tract returns to normal soon after the abortion. Trial results have demonstrated that an abortion rate of approximately 95% can be expected up to 4 1/2 months of gestation. The ability of cloprostenol to induce abortion decreases beyond 4 1/2 months while the risk of dystocia and its consequences increases.

Dosage and Administration

Juramate should be administered by INTRAMUSCULAR INJECTION. Only cattle with functional corpus luteum (CL) can respond to the luteolytic action of Juramate. In the cycling animal, there are refractory periods of 4 - 5 days before and after ovulation when cattle are not responding to prostaglandins.

The dose for therapeutic indications and for controlled breeding is 2 mL. For induction of abortion, the dose is 1.5 mL (or 2 mL for animals over 455 kg).

Injection regimes: For abortion and for therapeutic indications, give one injection. For controlled breeding, veterinarians and their client dairy and beef producers should select the controlled breeding program (A, B or C) which is appropriate for the existing circumstances and management practices.

First service conception rates in Canada using existing artificial insemination practices are generally agreed to be 40% - 60% for beef cattle and 50% - 60% for dairy cattle. The spread of calf crops indicates similar levels are attained using natural service. Field trial results have demonstrated that producers can achieve similar conception rates using cloprostenol. If existing management breeding practices are resulting in higher or lower conception rates, similar levels can be expected using Juramate. Following the controlled breeding program, those animals not conceiving should be re-bred. This may be done by:

- Observing animals for a return to estrus (especially during the third week after injection) and inseminating or hand mating animals returning to estrus, or

- Turning in clean-up bulls 7 - 8 days after the last injection to cover any animal returning to estrus.

Many factors affect conception rates. Before a controlled breeding program is planned, the producer and his consulting veterinarian should review the operation’s breeding history, herd health and nutritional status and agree that a controlled breeding program is practical in the producer’s specific situation. For a successful controlled breeding program:

- Cows and heifers must be cycling. Cattle should be palpated.

- Cattle should be in good condition for breeding. Animals in poor or medium condition should be fed to ensure a positive nutritional balance for 4 - 6 weeks before Juramate treatment and for 4 weeks after treatment.

- Proper program planning and record keeping are essential.

- Artificial insemination must be performed by competent inseminators using high quality semen. Inseminator fatigue must be avoided.

CONTRA-INDICATIONS: Since cloprostenol results in an abortion rate of approximately 95% in cattle up to 4 1/2 months of gestation and causes some cattle in later pregnancy to abort, it should not be given to pregnant animal unless induced abortion is desired.

CAUTIONS: A low incidence of clostridial and other infections at the injection site has been reported following prostaglandin administration. Treated animals should be closely observed post injection and appropriate antibiotic therapy initiated at the first signs of infection.

Warnings

Treated animals must not be slaughtered for use in food for at least 2 days after the latest treatment with this drug. No milk withholding period is required in cattle when used according to the label. Juramate can be absorbed through the skin. Therefore, care should be taken when handling the product, particularly by women of child-bearing age and by asthmatics. Accidental spillage on the skin should be washed off immediately with water. Prostaglandins of the F2a type may cause bronchospasm in man, although the possible incidence of this effect with Juramate is not known. Should respiratory distress result from accidental inhalation or injection, the inhalation of a rapid acting bronchodilator is indicated. Keep out of reach of children.

Adverse Reactions

At 50 and 100 times the recommended dose, mild side effects may be detected. These include increased uneasiness, mild transient diarrhea, slight frothing and milk let-down. Juramate has a good margin of safety, and no deleterious effects have been reported on the progeny conceived at the estrus following treatment.

Storage

Store at controlled room temperature (15°C to 30°C). Protect from light. Keep the vial in the outer carton.

PRESENTATION: Juramate is supplied in 20 ml multi-dose vials containing 250 µg of cloprostenol per mL.

Manufactured by Jurox Pty Limited, 85 Gardiner Road, Rutherford NSW 2320 Australia

Imported by Bimeda-MTC Animal Health Inc., 420 Beaverdale Road, Cambridge, Ontario N3C 2W4 Canada

460680

NAC No.: 14730050

BIMEDA-MTC ANIMAL HEALTH INC.
420 BEAVERDALE ROAD, CAMBRIDGE, ON, N3C 2W4
Telephone:   519-654-8000
Website:   www.bimedamtc.com
Every effort has been made to ensure the accuracy of the Juramate information published above. However, it remains the responsibility of the readers to familiarize themselves with the product information contained on the Canadian product label or package insert.

Copyright © 2016 North American Compendiums. Updated: 2016-10-31

Hide